161 related articles for article (PubMed ID: 35947646)
1. Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.
Merola D; Schneeweiss S; Sreedhara SK; Zabotka LE; Quinto K; Concato J; Wang SV
JNCI Cancer Spectr; 2022 Aug; 6(4):. PubMed ID: 35947646
[TBL] [Abstract][Full Text] [Related]
2. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH;
Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
6. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.
Crawford ED; Shore ND; Moul JW; Tombal B; Schröder FH; Miller K; Boccon-Gibod L; Malmberg A; Olesen TK; Persson BE; Klotz L
Urology; 2014 May; 83(5):1122-8. PubMed ID: 24661333
[TBL] [Abstract][Full Text] [Related]
8. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
9. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
11. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
12. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
[TBL] [Abstract][Full Text] [Related]
15. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Autio KA; Antonarakis ES; Mayer TM; Shevrin DH; Stein MN; Vaishampayan UN; Morris MJ; Slovin SF; Heath EI; Tagawa ST; Rathkopf DE; Milowsky MI; Harrison MR; Beer TM; Balar AV; Armstrong AJ; George DJ; Paller CJ; Apollo A; Danila DC; Graff JN; Nordquist L; Dayan Cohn ES; Tse K; Schreiber NA; Heller G; Scher HI
Eur Urol Open Sci; 2021 Dec; 34():70-78. PubMed ID: 34934969
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
Conover MM; Weaver J; Fan B; Leitz G; Richarz U; Li Q; Gifkins D
Prostate; 2023 May; 83(7):729-739. PubMed ID: 36879362
[TBL] [Abstract][Full Text] [Related]
19. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
[TBL] [Abstract][Full Text] [Related]
20. Degarelix.
Frampton JE; Lyseng-Williamson KA
Drugs; 2009 Oct; 69(14):1967-76. PubMed ID: 19747011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]